Literature DB >> 35105889

Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot.

Jörg Paetzold1, Hannes Winner2, Janine Kimpel3, Katie Bates4, Michael Hummer5, Florian Krammer6, Dorothee von Laer3.   

Abstract

We study the real-life effect of an unprecedented rapid mass vaccination campaign. Following a large outbreak of the Beta variant in the district of Schwaz/Austria, 100,000 doses of BNT162b2 (Pfizer/BioNTech) were procured to mass vaccinate the entire adult population of the district between the 11th and 16th of March 2021. This made the district the first widely inoculated region in Europe. We examine the effect of this campaign on the number of infections, cases of variants of concern, hospital and ICU admissions. We compare Schwaz with (i) a control group of highly similar districts, and (ii) with populations residing in municipalities along the border of Schwaz which were just excluded from the campaign. We find large and significant decreases for all outcomes after the campaign. Our results suggest that rapid mass vaccination is an effective tool to curb the spread of SARS-CoV-2.
© 2022. The Author(s).

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35105889      PMCID： PMC8807735          DOI： 10.1038/s41467-022-28233-8

Source DB:  PubMed          Journal:  Nat Commun        ISSN： 2041-1723            Impact factor:   14.919


  12 in total

1.  COVID-19 dynamics after a national immunization program in Israel.

Authors:  Malka Gorfine; Uri Shalit; Eran Segal; Hagai Rossman; Smadar Shilo; Tomer Meir
Journal:  Nat Med       Date:  2021-04-19       Impact factor: 53.440

2.  The Economic Consequences of Hospital Admissions.

Authors:  Carlos Dobkin; Amy Finkelstein; Raymond Kluender; Matthew J Notowidigdo
Journal:  Am Econ Rev       Date:  2018-02

3.  Detection of a SARS-CoV-2 variant of concern in South Africa.

Authors:  Houriiyah Tegally; Eduan Wilkinson; Marta Giovanetti; Arash Iranzadeh; Vagner Fonseca; Jennifer Giandhari; Deelan Doolabh; Sureshnee Pillay; Emmanuel James San; Nokukhanya Msomi; Koleka Mlisana; Anne von Gottberg; Sibongile Walaza; Mushal Allam; Arshad Ismail; Thabo Mohale; Allison J Glass; Susan Engelbrecht; Gert Van Zyl; Wolfgang Preiser; Francesco Petruccione; Alex Sigal; Diana Hardie; Gert Marais; Nei-Yuan Hsiao; Stephen Korsman; Mary-Ann Davies; Lynn Tyers; Innocent Mudau; Denis York; Caroline Maslo; Dominique Goedhals; Shareef Abrahams; Oluwakemi Laguda-Akingba; Arghavan Alisoltani-Dehkordi; Adam Godzik; Constantinos Kurt Wibmer; Bryan Trevor Sewell; José Lourenço; Luiz Carlos Junior Alcantara; Sergei L Kosakovsky Pond; Steven Weaver; Darren Martin; Richard J Lessells; Jinal N Bhiman; Carolyn Williamson; Tulio de Oliveira
Journal:  Nature       Date:  2021-03-09       Impact factor: 49.962

4.  mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.

Authors:  Hiam Chemaitelly; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Mohammad R Hasan; Joel A Malek; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Adeel A Butt; Roberto Bertollini; Laith J Abu-Raddad
Journal:  Nat Med       Date:  2021-07-09       Impact factor: 53.440

5.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.

Authors:  Nuno R Faria; Thomas A Mellan; Charles Whittaker; Ingra M Claro; Darlan da S Candido; Swapnil Mishra; Oliver G Pybus; Seth Flaxman; Samir Bhatt; Ester C Sabino; Myuki A E Crispim; Flavia C S Sales; Iwona Hawryluk; John T McCrone; Ruben J G Hulswit; Lucas A M Franco; Mariana S Ramundo; Jaqueline G de Jesus; Pamela S Andrade; Thais M Coletti; Giulia M Ferreira; Camila A M Silva; Erika R Manuli; Rafael H M Pereira; Pedro S Peixoto; Moritz U G Kraemer; Nelson Gaburo; Cecilia da C Camilo; Henrique Hoeltgebaum; William M Souza; Esmenia C Rocha; Leandro M de Souza; Mariana C de Pinho; Leonardo J T Araujo; Frederico S V Malta; Aline B de Lima; Joice do P Silva; Danielle A G Zauli; Alessandro C de S Ferreira; Ricardo P Schnekenberg; Daniel J Laydon; Patrick G T Walker; Hannah M Schlüter; Ana L P Dos Santos; Maria S Vidal; Valentina S Del Caro; Rosinaldo M F Filho; Helem M Dos Santos; Renato S Aguiar; José L Proença-Modena; Bruce Nelson; James A Hay; Mélodie Monod; Xenia Miscouridou; Helen Coupland; Raphael Sonabend; Michaela Vollmer; Axel Gandy; Carlos A Prete; Vitor H Nascimento; Marc A Suchard; Thomas A Bowden; Sergei L K Pond; Chieh-Hsi Wu; Oliver Ratmann; Neil M Ferguson; Christopher Dye; Nick J Loman; Philippe Lemey; Andrew Rambaut; Nelson A Fraiji; Maria do P S S Carvalho
Journal:  Science       Date:  2021-04-14       Impact factor: 47.728

6.  Preparing for COVID-19 vaccine roll-out through simulation exercises.

Authors:  Frederik A Copper; Cindy Chiu de Vázquez; Allan Bell; Landry Ndriko Mayigane; Liviu Vedrasco; Stella Chungong
Journal:  Lancet Glob Health       Date:  2021-03-03       Impact factor: 26.763

7.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

8.  Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.

Authors:  Eleftheria Vasileiou; Colin R Simpson; Ting Shi; Steven Kerr; Utkarsh Agrawal; Ashley Akbari; Stuart Bedston; Jillian Beggs; Declan Bradley; Antony Chuter; Simon de Lusignan; Annemarie B Docherty; David Ford; Fd Richard Hobbs; Mark Joy; Srinivasa Vittal Katikireddi; James Marple; Colin McCowan; Dylan McGagh; Jim McMenamin; Emily Moore; Josephine Lk Murray; Jiafeng Pan; Lewis Ritchie; Syed Ahmar Shah; Sarah Stock; Fatemeh Torabi; Ruby Sm Tsang; Rachael Wood; Mark Woolhouse; Chris Robertson; Aziz Sheikh
Journal:  Lancet       Date:  2021-04-23       Impact factor: 202.731

9.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Authors:  Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer
Journal:  N Engl J Med       Date:  2021-02-24       Impact factor: 91.245

10.  Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.

Authors:  Madhumita Shrotri; Maria Krutikov; Tom Palmer; Rebecca Giddings; Borscha Azmi; Sathyavani Subbarao; Christopher Fuller; Aidan Irwin-Singer; Daniel Davies; Gokhan Tut; Jamie Lopez Bernal; Paul Moss; Andrew Hayward; Andrew Copas; Laura Shallcross
Journal:  Lancet Infect Dis       Date:  2021-06-23       Impact factor: 25.071
View more
  4 in total

1.  Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale.

Authors:  Fabian Amman; Rudolf Markt; Lukas Endler; Sebastian Hupfauf; Benedikt Agerer; Anna Schedl; Lukas Richter; Melanie Zechmeister; Martin Bicher; Georg Heiler; Petr Triska; Matthew Thornton; Thomas Penz; Martin Senekowitsch; Jan Laine; Zsofia Keszei; Peter Klimek; Fabiana Nägele; Markus Mayr; Beatrice Daleiden; Martin Steinlechner; Harald Niederstätter; Petra Heidinger; Wolfgang Rauch; Christoph Scheffknecht; Gunther Vogl; Günther Weichlinger; Andreas Otto Wagner; Katarzyna Slipko; Amandine Masseron; Elena Radu; Franz Allerberger; Niki Popper; Christoph Bock; Daniela Schmid; Herbert Oberacher; Norbert Kreuzinger; Heribert Insam; Andreas Bergthaler
Journal:  Nat Biotechnol       Date:  2022-07-18       Impact factor: 68.164

2.  Can high COVID-19 vaccination rates in adults help protect unvaccinated children? Evidence from a unique mass vaccination campaign, Schwaz/Austria, March 2021.

Authors:  Hannes Winner; Janine Kimpel; Florian Krammer; Dorothee von Laer; Jörg Paetzold
Journal:  Euro Surveill       Date:  2022-09

3.  Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria.

Authors:  Zoltán Bánki; Lisa Seekircher; Barbara Falkensammer; David Bante; Helena Schäfer; Teresa Harthaller; Janine Kimpel; Peter Willeit; Dorothee von Laer; Wegene Borena
Journal:  Viruses       Date:  2022-07-27       Impact factor: 5.818

4.  Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak.

Authors:  Peter Willeit; Janine Kimpel; Hannes Winner; Teresa Harthaller; Helena Schäfer; David Bante; Barbara Falkensammer; Annika Rössler; Lydia Riepler; Cornelia Ower; Magdalena Sacher; Dorothee von Laer; Wegene Borena
Journal:  Front Public Health       Date:  2022-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.